All News

Nurses at West Cancer Center in Memphis, Tennessee, developed a best nursing practice protocol for titration of fentanyl sublingual spray (FSS; Subsys) for breakthrough cancer pain.

Nurses and oncologists need to give portal vein thrombosis a closer look, according to one oncolgy nurse.

On making choices based on hopes and dreams and not fear of a reccurance.

Lymphedema presents clothing challenges.

Patients with cancer who are also a part of the LGBT community often face barriers when it comes to the care and treatment for their disease.

Multiple presenters at the 41st Annual Oncology Nursing Society Congress addressed risk and prevention of falls in patients with cancer, as it is a growing concern for health care providers.

Blessed are the caregivers, says two-time cancer survivor who is now helping her older mom cope with cancer.

It makes perfect sense to me now that exhaustion is one of the byproducts of cancer treatment. As blood counts drop, cells die, and the mental stress and strain builds, the vital energy force no longer flows like a raging river—it has all the power of a dripping faucet.

I am not a warrior who can handle anything. I am not the toughest person you know. I have no choice.

A team approach to treatment could improve outcomes for patients with head and neck cancer.

In an interview with CURE, John L. Marshall emphasized that treating GI cancers is a "team sport."

Being covered in cat fur feels wonderful.

Only medical research can beat cancer, and the tragedy of cancer deaths cannot be softened.

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma (HCC), including a host of targeted therapies and various immune checkpoint inhibitors.

In an interview with CURE, DeMichele explains the significance of the I-SPY 2 data, the advantages of Kadcyla versus standard of care and what is on the horizon for the use of Kadcyla in HER2-positive disease.

Cancer is often about quantity when it should be about quality.

The first-line treatment paradigm for lung cancer is shifting.

Thanks to an addition of three biological markers to conventional breast cancer risk models, women can now better determine if they are at high or low risk for developing the disease.

It's not always smooth sailing with breast cancer.

The FDA approved Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.

The FDA granted Opdivo (nivolumab) a breakthrough therapy designation to treat certain patients with head and neck cancer.

The combination of Yervoy and Opdivo showed a 42 percent improvement in overall survival compared with Yervoy monotherapy for patients with advanced melanoma in a two-year assessment of the phase 2 CheckMate-069 trial.

Cancer survivor confesses she has become nicer since cancer.

A phase 3 study presented at the 2016 AACR Annual Meeting showed that Opdivo doubled one-year survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma.

The FDA granted Keytruda a breakthrough therapy designation after success in early trials. Information from the phase 2 trial will soon be presented.

Signs of worry and hope as seasons slowly change

Opdivo (nivolumab) is showing promise for patients with metastatic melanoma.

Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.